Metastatic lung cancer patient finds effective therapy in clinical trial

Treatment Terms Lung cancer Additional SEO Keywords lung cancer, metastatic cancer, metastatic lung cancer, brain metastases, clinical trial, cancer clinical trial, experimental cancer medication, experimental cancer therapy SEO Meta Description Ginger Scott needed new options to treat her metastatic lung cancer. A clinical trial at Duke gave her just that. Author MaryAnn Fletcher Overview Ginger Scott needed new options to treat her metastatic lung cancer. A clinical trial at Duke gave her just that. Hero Image 20160706.scott_.ginger.blog_.01.jpg Preview Image Content Blocks Content Scott, a healthy, athletic 40-year-old mom of three, was in her Whiteville, NC, home, preparing food for a holiday party when she began to feel dizzy. “I thought, ‘Oh, I must need something to drink’ and took a break,” said Scott. “Within 20 seconds, I went into a full grand-mal seizure.” A series of scans revealed the cause of her seizure: tumors in her brain that had spread from her lung. A biopsy confirmed that Scott, who had never smoked, had non-small cell lung cancer. Almost immediately, she began receiving radiation treatment. She also began taking an oral medication targeted to her type of cancer. Scott’s cancer cells had an EGFR mutation, meaning they had an overactive form of a protein called epidermal growth factor receptor (EGFR) on their surface, wh...
Source: dukehealth.org: Duke Health News - Category: Consumer Health News Authors: Source Type: news

Related Links:

Conclusion: Our data supports that never/ever smoker patients with small-cell lung cancer have better prognosis compared to their smoker counterparts. Further, patients with never/ever smoking history who present with small-cell lung cancer have a different mutation profile compared with smokers, including a high frequency of EGFR, MET, and SMAD4 mutations. Further studies are required to assess whether the differential mutation profile is a consequence of a diverse pathological mechanism for disease onset. Introduction Lung cancer is the most common neoplasia worldwide. Aside from the high incidence, lung cancer a...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion Most head and neck pathologies show a broad cellular heterogeneity making it difficult to achieve an accurate diagnosis and efficient treatment (Graf and Zavodszky, 2017; Lo Nigro et al., 2017). Single cell analysis of circadian omics (Lande-Diner et al., 2015; Abraham et al., 2018), may be a crucial tool needed in the future to fully understand the circadian control of head and neck diseases. It becomes more obvious that there is only a small genetic component but a largely unknown epigenetics and/or environmental component for most of the head and neck pathologies (Moosavi and Motevalizadeh Ardekani, 2016; He...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroinfla...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionCrizotinib was effective and well tolerated in Chinese patients withROS1-positive advanced NSCLC in real-world clinical practice. The progression sites and patterns, as well as treatments after first disease progression on crizotinib were diverse. Crizotinib beyond progressive disease and local therapy after failure of crizotinib treatment were feasible and effective in clinical practice.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Our findings suggest that YH25448 is a promising third-generation EGFR inhibitor, which may be more effective and better tolerated than the currently approved osimertinib. PMID: 30670498 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract Lorlatinib, a novel generation oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor with high membrane and blood-brain barrier permeability, recently received accelerated approval for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), and its further clinical development is ongoing. We previously found that the efflux transporter P-glycoprotein (MDR1/ABCB1) restricts lorlatinib brain accumulation and that the drug-metabolizing enzyme cytochrome P450-3A (CYP3A) limits its oral availability. Using genetically modified mouse models, we investigated the impact of targeted pharmacological inhi...
Source: European Journal of Pharmaceutics and Biopharmaceutics - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Biopharm Source Type: research
Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). D...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Publication date: November 2018Source: Pharmacological Research, Volume 137Author(s): Wenlong Li, Rolf W. Sparidans, Yaogeng Wang, Maria C. Lebre, Jos H. Beijnen, Alfred H. SchinkelAbstractBrigatinib is an FDA-approved oral anaplastic lymphoma kinase (ALK) inhibitor for treatment of metastatic non-small cell lung cancer (NSCLC). Using genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, and the multispecific drug-metabolizing enzyme CYP3 A in plasma pharmacokinetics and tissue distribution of brigatinib. In vitro, brigatinib was exceptionally well transpo...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Conclusions: Exact incidence of T790M mutations after progression on TKI s in Asian population is not exactly known and requires large data, as incidence may be different than reported in the Western population. Rebiopsy and ddPCR help to determine the most common type of resistance after progression on TKI, for which effective targeted therapy is available.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
Authors: Alshangiti A, Chandhoke G, Ellis PM Abstract Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular endothelial growth factor, in combination with carboplatin-paclitaxel chemotherapy, has been shown to improve survival for patients with nsclc. However, bevacizumab-based therapy is not suitable for many nsclc patients, including those with squamous histology, poor pe...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Blogging | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Ginger | Health | Learning | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Oral Cancer | PET Scan | Smokers | Universities & Medical Training